Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy

A. D. Steinberg, M. C. Gelfand, J. A. Hardin, D. T. Lowenthal

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Female NZB/W mice develop a disease closely resembling human systemic lupus and serve as an animal model for therapeutic studies. Several previous studies have demonstrated the efficacy of different immunosuppressive drug regimens in the therapy of glomerulonephritis in NZB/W mice. After the onset of immune complex deposition, treatment with intermittent high doses of cyclophosphamide or daily low doses of the combination of cyclophosphamide, azathioprine, and methylprednisolone has been effective. The present study was designed to compare such effective regimens in mice early in the course of their renal disease versus mice late in the course of glomerulonephritis. One to three injections of high dose cyclophosphamide during active immune complex deposition and early histologic changes were significantly effective in prolonging survival, whereas treatment late in the course of glomerulonephritis was less effective. Even more striking was the result of low dose combination therapy. Daily treatment with cyclophosphamide, azathioprine, and methylprednisolone (C + A + M) effectively prolonged survival when started in mice 5 mth old, but was of no benefit when started in those 8 mth of age. In a concluding experiment, older mice were selected on the basis of degree of renal disease and studied with regard to proteinuria and survival. Those with mild renal disease responded to daily treatment for 6 mth with C + A + A at 1 mg/kg of each drug, whereas those with advanced renal disease at the onset of therapy did not benefit.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalArthritis and Rheumatism
Volume18
Issue number1
StatePublished - 1975
Externally publishedYes

Fingerprint

Inbred NZB Mouse
Immunosuppressive Agents
Kidney
Drug Therapy
Cyclophosphamide
Glomerulonephritis
Methylprednisolone
Azathioprine
Therapeutics
Antigen-Antibody Complex
Survival
Proteinuria
Pharmaceutical Preparations
Animal Models
Injections

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy. / Steinberg, A. D.; Gelfand, M. C.; Hardin, J. A.; Lowenthal, D. T.

In: Arthritis and Rheumatism, Vol. 18, No. 1, 1975, p. 9-14.

Research output: Contribution to journalArticle

Steinberg, A. D. ; Gelfand, M. C. ; Hardin, J. A. ; Lowenthal, D. T. / Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy. In: Arthritis and Rheumatism. 1975 ; Vol. 18, No. 1. pp. 9-14.
@article{1d495ea14ee3492681c9d399a4636227,
title = "Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy",
abstract = "Female NZB/W mice develop a disease closely resembling human systemic lupus and serve as an animal model for therapeutic studies. Several previous studies have demonstrated the efficacy of different immunosuppressive drug regimens in the therapy of glomerulonephritis in NZB/W mice. After the onset of immune complex deposition, treatment with intermittent high doses of cyclophosphamide or daily low doses of the combination of cyclophosphamide, azathioprine, and methylprednisolone has been effective. The present study was designed to compare such effective regimens in mice early in the course of their renal disease versus mice late in the course of glomerulonephritis. One to three injections of high dose cyclophosphamide during active immune complex deposition and early histologic changes were significantly effective in prolonging survival, whereas treatment late in the course of glomerulonephritis was less effective. Even more striking was the result of low dose combination therapy. Daily treatment with cyclophosphamide, azathioprine, and methylprednisolone (C + A + M) effectively prolonged survival when started in mice 5 mth old, but was of no benefit when started in those 8 mth of age. In a concluding experiment, older mice were selected on the basis of degree of renal disease and studied with regard to proteinuria and survival. Those with mild renal disease responded to daily treatment for 6 mth with C + A + A at 1 mg/kg of each drug, whereas those with advanced renal disease at the onset of therapy did not benefit.",
author = "Steinberg, {A. D.} and Gelfand, {M. C.} and Hardin, {J. A.} and Lowenthal, {D. T.}",
year = "1975",
language = "English (US)",
volume = "18",
pages = "9--14",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy

AU - Steinberg, A. D.

AU - Gelfand, M. C.

AU - Hardin, J. A.

AU - Lowenthal, D. T.

PY - 1975

Y1 - 1975

N2 - Female NZB/W mice develop a disease closely resembling human systemic lupus and serve as an animal model for therapeutic studies. Several previous studies have demonstrated the efficacy of different immunosuppressive drug regimens in the therapy of glomerulonephritis in NZB/W mice. After the onset of immune complex deposition, treatment with intermittent high doses of cyclophosphamide or daily low doses of the combination of cyclophosphamide, azathioprine, and methylprednisolone has been effective. The present study was designed to compare such effective regimens in mice early in the course of their renal disease versus mice late in the course of glomerulonephritis. One to three injections of high dose cyclophosphamide during active immune complex deposition and early histologic changes were significantly effective in prolonging survival, whereas treatment late in the course of glomerulonephritis was less effective. Even more striking was the result of low dose combination therapy. Daily treatment with cyclophosphamide, azathioprine, and methylprednisolone (C + A + M) effectively prolonged survival when started in mice 5 mth old, but was of no benefit when started in those 8 mth of age. In a concluding experiment, older mice were selected on the basis of degree of renal disease and studied with regard to proteinuria and survival. Those with mild renal disease responded to daily treatment for 6 mth with C + A + A at 1 mg/kg of each drug, whereas those with advanced renal disease at the onset of therapy did not benefit.

AB - Female NZB/W mice develop a disease closely resembling human systemic lupus and serve as an animal model for therapeutic studies. Several previous studies have demonstrated the efficacy of different immunosuppressive drug regimens in the therapy of glomerulonephritis in NZB/W mice. After the onset of immune complex deposition, treatment with intermittent high doses of cyclophosphamide or daily low doses of the combination of cyclophosphamide, azathioprine, and methylprednisolone has been effective. The present study was designed to compare such effective regimens in mice early in the course of their renal disease versus mice late in the course of glomerulonephritis. One to three injections of high dose cyclophosphamide during active immune complex deposition and early histologic changes were significantly effective in prolonging survival, whereas treatment late in the course of glomerulonephritis was less effective. Even more striking was the result of low dose combination therapy. Daily treatment with cyclophosphamide, azathioprine, and methylprednisolone (C + A + M) effectively prolonged survival when started in mice 5 mth old, but was of no benefit when started in those 8 mth of age. In a concluding experiment, older mice were selected on the basis of degree of renal disease and studied with regard to proteinuria and survival. Those with mild renal disease responded to daily treatment for 6 mth with C + A + A at 1 mg/kg of each drug, whereas those with advanced renal disease at the onset of therapy did not benefit.

UR - http://www.scopus.com/inward/record.url?scp=0016699229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016699229&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 9

EP - 14

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -